CMS finalises permanent framework for Medicare Drug Price Negotiation Program from 2029
The US agency has set lasting policies for negotiating prices of high-cost drugs under Medicare, giving manufacturers more predictability for prices taking effect from 2029.
The US Centers for Medicare & Medicaid Services (CMS) has finalised a permanent framework for the Medicare Drug Price Negotiation Program. The rule, announced on 5 November 2026, sets out the policies that will govern how prices for high-cost drugs are negotiated.
The framework applies to negotiated prices that take effect from 2029. According to CMS, it is intended to give participating manufacturers greater predictability about how the negotiation process will work.
The full text of the final rule was not available for this report, so details such as selection criteria, timelines, and the treatment of specific product categories are not covered here. Companies will need to consult the published rule for the operational detail.
The change bears mainly on pricing, market access and commercial planning. It has little direct relevance to pharmacovigilance.
What it means for your team
- Market-access and pricing teams should review the final rule to understand how negotiation will operate for prices effective from 2029.
- Commercial planners can use the permanent framework, rather than interim arrangements, as the basis for longer-term scenario planning.
- Regulatory and PV teams are unlikely to face direct obligations from this rule, though they may be asked to support related company data requests.
Article written by VigiEye from the official source (CMS). AI-assisted; check the source before acting.
Market accessCompany releaseMedicare begins paying for Lucid's EsoGuard as PAVmed's Veris nears FDA 510(k) filing
Market accessOfficialDenmark updates Voltabak eye drop supply notice, with shortage expected to run to mid-May 2027
Market accessOfficialMethergin 0.2 mg/ml injection withdrawn from Danish market, DKMA reports
Market accessOfficialDenmark updates import window for estradiol 25 microgram patches in supply failure
Market accessOfficialDKMA updates Vivelle Dot 37.5 supply notice: shortage expected to last until end of December
Market accessOfficial